IN8bio (INAB) Competitors $2.17 -0.03 (-1.36%) Closing price 04:00 PM EasternExtended Trading$2.26 +0.09 (+3.92%) As of 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock INAB vs. TPST, NRSN, CVKD, CGTX, ALXO, CARA, TENX, OVID, CYTH, and CTXRShould you be buying IN8bio stock or one of its competitors? The main competitors of IN8bio include Tempest Therapeutics (TPST), NeuroSense Therapeutics (NRSN), Cadrenal Therapeutics (CVKD), Cognition Therapeutics (CGTX), ALX Oncology (ALXO), Cara Therapeutics (CARA), Tenax Therapeutics (TENX), Ovid Therapeutics (OVID), Cyclo Therapeutics (CYTH), and Citius Pharmaceuticals (CTXR). These companies are all part of the "pharmaceutical products" industry. IN8bio vs. Its Competitors Tempest Therapeutics NeuroSense Therapeutics Cadrenal Therapeutics Cognition Therapeutics ALX Oncology Cara Therapeutics Tenax Therapeutics Ovid Therapeutics Cyclo Therapeutics Citius Pharmaceuticals Tempest Therapeutics (NASDAQ:TPST) and IN8bio (NASDAQ:INAB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, risk, media sentiment, profitability and institutional ownership. Does the media favor TPST or INAB? In the previous week, Tempest Therapeutics' average media sentiment score of 1.89 beat IN8bio's score of 0.94 indicating that Tempest Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Tempest Therapeutics Very Positive IN8bio Positive Do analysts recommend TPST or INAB? Tempest Therapeutics presently has a consensus target price of $30.00, indicating a potential upside of 376.19%. IN8bio has a consensus target price of $180.00, indicating a potential upside of 8,194.93%. Given IN8bio's stronger consensus rating and higher probable upside, analysts plainly believe IN8bio is more favorable than Tempest Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tempest Therapeutics 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50IN8bio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders believe in TPST or INAB? 22.5% of Tempest Therapeutics shares are owned by institutional investors. Comparatively, 92.1% of IN8bio shares are owned by institutional investors. 4.7% of Tempest Therapeutics shares are owned by insiders. Comparatively, 15.5% of IN8bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is TPST or INAB more profitable? IN8bio's return on equity of -218.85% beat Tempest Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Tempest TherapeuticsN/A -305.51% -119.74% IN8bio N/A -218.85%-139.59% Which has better earnings and valuation, TPST or INAB? Tempest Therapeutics is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTempest TherapeuticsN/AN/A-$41.84M-$17.98-0.35IN8bioN/AN/A-$30.44M-$13.57-0.16 SummaryIN8bio beats Tempest Therapeutics on 8 of the 11 factors compared between the two stocks. Get IN8bio News Delivered to You Automatically Sign up to receive the latest news and ratings for INAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INAB vs. The Competition Export to ExcelMetricIN8bioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.66M$2.96B$5.54B$9.41BDividend YieldN/A2.46%3.75%4.03%P/E Ratio-0.168.2821.0120.09Price / SalesN/A303.17433.8199.01Price / CashN/A42.5936.1658.27Price / Book0.367.678.125.65Net Income-$30.44M-$55.28M$3.25B$257.91M7 Day Performance-5.24%2.50%0.97%2.09%1 Month Performance1.88%11.70%7.36%11.13%1 Year Performance-91.44%4.89%31.31%18.40% IN8bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INABIN8bio3.4741 of 5 stars$2.17-1.4%$180.00+8,194.9%-91.5%$6.66MN/A-0.1620TPSTTempest Therapeutics2.3833 of 5 stars$7.08-0.7%$30.00+323.7%-75.6%$26.26MN/A-0.3920Positive NewsNRSNNeuroSense Therapeutics2.5015 of 5 stars$2.09+9.4%$14.00+569.9%+150.1%$26.10MN/A-3.8710CVKDCadrenal Therapeutics2.9665 of 5 stars$12.95-0.2%$32.00+147.1%N/A$25.53MN/A-1.404CGTXCognition Therapeutics2.9505 of 5 stars$0.58+42.9%$2.83+389.5%-64.6%$25.11MN/A-0.7820High Trading VolumeALXOALX Oncology3.4874 of 5 stars$0.44-3.5%$3.30+643.2%-93.6%$24.57MN/A-0.1840Gap DownCARACara Therapeutics0.2147 of 5 starsN/AN/AN/A$24.33M$7.14M-0.2580News CoverageGap DownHigh Trading VolumeTENXTenax Therapeutics1.5517 of 5 stars$5.75-1.0%$17.50+204.3%+70.9%$24.10MN/A-2.329OVIDOvid Therapeutics4.6769 of 5 stars$0.37+10.5%$3.13+735.6%-53.0%$24.06M$570K-1.0760Gap UpHigh Trading VolumeCYTHCyclo TherapeuticsN/A$0.72flat$0.95+31.8%N/A$23.72M$870.73K-0.809CTXRCitius Pharmaceuticals3.0708 of 5 stars$2.11-4.5%$53.00+2,411.8%-92.2%$23.50MN/A0.0020High Trading Volume Related Companies and Tools Related Companies TPST Competitors NRSN Competitors CVKD Competitors CGTX Competitors ALXO Competitors CARA Competitors TENX Competitors OVID Competitors CYTH Competitors CTXR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INAB) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredFREE BUY ALERT: These 3 tiny AI stocks could surgeWe're living in unprecedented times. Most people think it's too late to get into AI right now … That the...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IN8bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IN8bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
